~ Buy the XIFAXAN (rifaximin) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR XIFAXAN

All Clinical Trials for Xifaxan

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00269399 ↗	A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)	Completed	Bausch Health Americas, Inc.	Phase 3	2005-12-01	The purpose of this study is to assess the treatment and safety of a 10-day course of rifaximin (Xifaxan) as compared to vancomycin for treatment of Clostridium difficile-associated diarrhea (CDAD).
NCT00269399 ↗	A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)	Completed	Valeant Pharmaceuticals International, Inc.	Phase 3	2005-12-01	The purpose of this study is to assess the treatment and safety of a 10-day course of rifaximin (Xifaxan) as compared to vancomycin for treatment of Clostridium difficile-associated diarrhea (CDAD).
NCT00577772 ↗	Transit Time and Bacterial Overgrowth Using SmartPill Capsule	Terminated	The SmartPill Corporation	N/A	2007-11-01	The primary purpose of this exploratory study is to measure orocecal transit time using the SmartPill ambulant capsule technology and to compare this with the lactulose hydrogen breath test. Additionally, the ability of the SmartPill GI Monitoring System to discriminate between healthy human subjects and patients with small bowel bacterial overgrowth will be explored using analyses of both pH and pressure patterns within the stomach and small intestine. The study will be performed in both normal subjects and patients with and without small bowel bacterial overgrowth.
NCT00577772 ↗	Transit Time and Bacterial Overgrowth Using SmartPill Capsule	Terminated	Mayo Clinic	N/A	2007-11-01	The primary purpose of this exploratory study is to measure orocecal transit time using the SmartPill ambulant capsule technology and to compare this with the lactulose hydrogen breath test. Additionally, the ability of the SmartPill GI Monitoring System to discriminate between healthy human subjects and patients with small bowel bacterial overgrowth will be explored using analyses of both pH and pressure patterns within the stomach and small intestine. The study will be performed in both normal subjects and patients with and without small bowel bacterial overgrowth.
NCT00603616 ↗	Induction of Clinical Response Using Rifaximin in Crohn's Disease	Completed	Bausch Health Americas, Inc.	Phase 2	2008-11-01	Antibiotics have been used to treat Crohn's disease symptoms with the best studied antibiotics being Cipro and Flagyl. Rifaximin is a poorly absorbed oral antibiotic that is FDA approved for travelers' diarrhea. It works by inhibiting bacterial reproduction. It is very poorly absorbed and over 97% of the drug taken orally is excreted in the feces. The purpose of this study is to evaluate the potential benefits and safety of Rifaximin for the treatment of moderate to severe symptoms of Crohn's Disease.
NCT00603616 ↗	Induction of Clinical Response Using Rifaximin in Crohn's Disease	Completed	Valeant Pharmaceuticals International, Inc.	Phase 2	2008-11-01	Antibiotics have been used to treat Crohn's disease symptoms with the best studied antibiotics being Cipro and Flagyl. Rifaximin is a poorly absorbed oral antibiotic that is FDA approved for travelers' diarrhea. It works by inhibiting bacterial reproduction. It is very poorly absorbed and over 97% of the drug taken orally is excreted in the feces. The purpose of this study is to evaluate the potential benefits and safety of Rifaximin for the treatment of moderate to severe symptoms of Crohn's Disease.
NCT00603616 ↗	Induction of Clinical Response Using Rifaximin in Crohn's Disease	Completed	Scott Lee	Phase 2	2008-11-01	Antibiotics have been used to treat Crohn's disease symptoms with the best studied antibiotics being Cipro and Flagyl. Rifaximin is a poorly absorbed oral antibiotic that is FDA approved for travelers' diarrhea. It works by inhibiting bacterial reproduction. It is very poorly absorbed and over 97% of the drug taken orally is excreted in the feces. The purpose of this study is to evaluate the potential benefits and safety of Rifaximin for the treatment of moderate to severe symptoms of Crohn's Disease.

Clinical Trial Conditions for Xifaxan

Condition Name

Condition Name for Xifaxan
Intervention	Trials
Small Intestinal Bacterial Overgrowth	4
Cirrhosis	4
Irritable Bowel Syndrome	3
Hepatic Encephalopathy	3

Condition MeSH

Condition MeSH for Xifaxan
Intervention	Trials
Diarrhea	7
Syndrome	5
Irritable Bowel Syndrome	5
Hepatic Encephalopathy	5

Clinical Trial Locations for Xifaxan

Trials by Country

Trials by Country for Xifaxan
Location	Trials
United States	83
China	3
Germany	2
Norway	2
Puerto Rico	1

Trials by US State

Trials by US State for Xifaxan
Location	Trials
California	9
Florida	6
Georgia	4
Arizona	4
Texas	4

Clinical Trial Progress for Xifaxan

Clinical Trial Phase

Clinical Trial Phase for Xifaxan
Clinical Trial Phase	Trials
Phase 4	7
Phase 3	6
Phase 2	10

Clinical Trial Status

Clinical Trial Status for Xifaxan
Clinical Trial Phase	Trials
Completed	19
Terminated	5
Recruiting	5

Clinical Trial Sponsors for Xifaxan

Sponsor Name

Sponsor Name for Xifaxan
Sponsor	Trials
Bausch Health Americas, Inc.	8
Valeant Pharmaceuticals International, Inc.	8
Mayo Clinic	4

Sponsor Type

Sponsor Type for Xifaxan
Sponsor	Trials
Other	47
Industry	21
U.S. Fed	7